Masimo (MASI) Launches UniView, Improves Patient Safety

In a bid to reduce clinician cognitive overload and improve patient safety, Masimo Corporation (NASDAQ:MASI) announced the launch of UniView — an integrated platform that displays real-time data and alarms from multiple Masimo and third-party devices.

An expanding product portfolio and higher adoption of its non-invasive patient monitoring technology are major growth catalysts for Masimo. The stock has a Zacks Rank #2 (Buy).

What is UniView?

UniView unifies data from a variety of sources — such as patient monitors, ventilators, anesthesia gas machines and IV pumps. The platform optimizes the presentation of parameters, trend data and waveforms for a variety of clinical scenarios, which makes it a versatile solution in many environments.

Notably, UniView builds on Masimo’s Kite platform, which projects data from Root on a larger screen, by aggregating data from all of the connected devices in a room.

UniView is also compatible with Masimo Iris Gateway and Patient SafetyNet connectivity platforms.

Apart from UniView, Masimo’s recently introduced Masimo Replica also deserves a mention. The platform allows clinicians to view similar monitoring data and respond to alarms as well as alerts from a smart phone, regardless of location.

Analysts believe that these developments will provide cushion to the stock that has declined 5.5% in a year’s time, against the industry’s rally of 21.6%.

Bottom Line

Masimo continues to gain from a solid product portfolio. The company’s unique strategy of launching products that target the general floor of hospitals and consumer market is likely to provide it a competitive edge in the U.S. MedTech sector.

The company introduced MightySat fingertip pulse oximeter for personal use. Products like Patient SafetyNet Series 5000, O3 regional oximetry, iSpO2 Mobile health pulse oximeter for Android are noteworthy.

The company’s flagship SET pulse oximeter solution is rapidly gaining traction over conventional pulse oximeters. Further, its newborn screening application, Eve, recently received CE Mark.

Other Key Picks

A few other top-ranked stocks in the broader medical sector are athenahealth, Inc. (NASDAQ:ATHN) , Bio-Rad Laboratories, Inc. (NYSE:BIO) and Centene Corporation (NYSE:CNC) . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

athenahealth has an expected long-term growth rate of 17.7% and projected earnings per share growth rate of 21.5%.

Bio-Rad has an expected long-term growth rate of 20% and projected earnings per share growth rate of 20%.

Centene has an expected long-term growth rate of 14.4% and projected earnings per share growth rate of 14.4%.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>